Compare Expeditors International of Wshngtn Inc (EXPD) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Novo Nordisk A/S — how do they compare? Expeditors International of Wshngtn Inc trades at $193.74 (market cap $24.81B), while Novo Nordisk A/S trades at $38.11 (market cap $168.73B). The key difference: Novo Nordisk A/S is far larger — about 6.8× Expeditors International of Wshngtn Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.7%). Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and Novo Nordisk A/S for 116 Days on average.
| EXPD | NVO | |
|---|---|---|
Market Cap | $24.81B | $168.73B |
Volume | 832,787 | 13,531,267 |
Sector | Industrials | Health |
52-Week High | $194.12 | $63.98 |
52-Week Low | $113.13 | $35.29 |
Typical Hold Time | 43 Days | 116 Days |
Enterprise Value | $24.34B | $183.05B |
Dividend Yield | 0.85% | 4.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $193.71, up 1.0% with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with 42.6% ROE and has beaten earnings estimates for three consecutive quarters. Recent news highlights efficiency initiatives and resilient airfreight demand as positive catalysts. Institutional activity shows mixed positioning with some major funds increasing stakes while others reduced exposure.
While EXPD shows strong operational metrics and earnings momentum, the stock trades above analyst consensus target of $174.86, suggesting limited near-term upside. Risks include competitive pressures and potential freight market volatility. The company's focus on efficiency and shareholder returns provides stability, but valuation remains elevated at 27.78 P/E ratio.
Novo Nordisk (NVO) trades at $38.18, up 1.73% with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat estimates, with Q2 2026 EPS of $0.96 surpassing the $0.82 expectation. The company maintains robust cash flow generation of $119.1B from operations in 2025.
NVO presents compelling value with a 9.71 P/E ratio and 16.8% upside to the $44.67 consensus target. Key risks include FDA regulatory delays for hemophilia drug denecimig and intensifying competition from Eli Lilly in obesity treatments. The bullish analyst consensus (59% buy ratings) supports the growth outlook despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
